Results 71 to 80 of about 3,690 (153)

Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient

Microbiology Spectrum
Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P.
Joaquim Viñes, Sabina Herrera, Andrea Vergara, Ignasi Roca, Jordi Vila, Tommaso Francesco Aiello, José Antonio Martínez, Ana del Río, Carlos Lopera, Carolina Garcia-Vidal, Climent Casals-Pascual, Àlex Soriano, Cristina Pitart   +12 more
doaj   +1 more source

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals

Annals of Clinical Microbiology and Antimicrobials
Abstract Background During prolonged FDC therapy, the emergence of FDC non-susceptibility in CRAB has been reported. Here, we report a transmission cluster of FDC-non-susceptible CRAB in four patients, all naïve to FDC treatment, characterized by a premature stop codon and amino acid deletion in the PirA protein.
Alteri, Claudia, Teri, Antonio, Liporace, Maria Francesca, Muscatello, Antonio, Terranova, Leonardo, Schianca, Margherita Carnevale, Salari, Federica, Orena, Beatrice Silvia, Silverj, Flaminia Gentiloni, Bernazzani, Mara, Biscarini, Simona, Renisi, Giulia, Cariani, Lisa, Matinato, Caterina, Canetta, Ciro, Bandera, Alessandra, Callegaro, Annapaola   +16 more
openaire   +3 more sources

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages

Scientific Reports
Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug ...
Rima Fanaei Pirlar, Nexhmije Halili, Tina Travnik, Andrej Trampuz, Svetlana Karbysheva   +4 more
doaj   +1 more source

Cefiderocol. Summary and conclusions

Revista Española de Quimioterapia, 2022
Mensa, José, Barberán, José
openaire   +2 more sources

Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement. [PDF]

Infect Dis Ther
Bleibtreu A, Bennis Y, Dinh A, Dupont H, Friggeri A, Jeannot K, Kipnis E, Zahar JR, CoRIS Cohort.   +8 more
europepmc   +1 more source

A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant <i>Achromobacter xylosoxidans</i>. [PDF]

Antimicrob Agents Chemother
Arun B, Sharma R, Vallé Q, Bui NM, Furtado N, Ramirez MS, Rao G.   +6 more
europepmc   +1 more source

Activity of novel antibiotics against dual metallo-Beta-lactamase producing Enterobacter hormaechei clinical isolates. [PDF]

JAC Antimicrob Resist
Solar C, Diaz L, Soto K, Martínez JRW, Canales N, Bergman Y, Peters A, Araos R, García P, Tamma PD, Munita JM.   +10 more
europepmc   +1 more source

Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]

mBio
Mezcord V, Luu I, Akhar U, Traglia GM, Rodríguez C, Moheb S, Sanchez SD, Soto MT, Cima Clave MJ, Sieira R, Tuttobene MR, Corso A, Tolmasky ME, Bonomo RA, Actis LA, Rao G, Pasteran F, Ramirez MS.   +17 more
europepmc   +1 more source

In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes. [PDF]

J Antimicrob Chemother
Raro OHF, Findlay J, Poirel L, Decousser JW, Nordmann P.   +4 more
europepmc   +1 more source

Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa. [PDF]

J Antimicrob Chemother
Yamano Y, Takemura M, Longshaw C, DeJonge BLM, Ishibashi N, Ishii R, Miyagawa D, Nakamura R, Kuroiwa M, Ishioka Y, Adachi T, Rokushima M, Maki H, Sato T.   +13 more
europepmc   +1 more source